Daniel Delgado Seneor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Delgado Seneor has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Wladimir Bocca Vieira de Rezende Pinto
Neurometabolic Unit, Division of Neuromuscular Diseases, Department of Neurology and Neurosurgery, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil
5 shared publications - Acary Souza Bulle Oliveira
Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo SP, Brazil
4 shared publications - Paulo Victor Sgobbi de Souza
Division of Neuromuscular Diseases, Department of Neurology and Neurosurgery, Federal University of São Paulo (UNIFESP), São Paulo 04039-060, Brazil
3 shared publications Igor Braga Farias
2 shared publications- Igor Braga Farias
Division of Neuromuscular Diseases, Department of Neurology and Neurosurgery, Federal University of São Paulo (UNIFESP), São Paulo 04039-060, Brazil
2 shared publications - João Paulo Barile
Division of Neuromuscular Diseases, Department of Neurology and Neurosurgery, Federal University of São Paulo (UNIFESP), São Paulo 04039-060, Brazil
2 shared publications
Latest Publications
- Open Access
- 20 July 2026
- Published by Elsevier in SSRN Electronic Journal
Clinical spectrum of TOP3A-related disorder: a case report and structured review of reported cases
The enzyme Topoisomerase III alpha (encoded by the gene TOP3A) constitutes an important part of the dissolvasome complex and participates in genomic stability in the nucleus and the mitochondria. Biallelic disease-causing mutations TOP3A are linked to a rare multi-system condition that has some similarities with Bloom syndrome but differentiating characteristics. To further expand the clinical, radiological, and genetic characterization of this condition, we describe a novel patient carrying two previously unreported genetic variants. In addition, a structured review of all previously reported cases in the literature was performed. A total of 27 individuals, among them the newly described patient and patients described in 6 other indexed papers, were included. Two partly overlapping phenotypes were identified: the early-onset type involving prenatal growth retardation, microcephaly, and cardiomyopathy, and the late-onset type involving mitochondrial dysfunction symptoms, such as progressive external ophthalmoplegia, cerebellar ataxia, peripheral neuropathy, as well as distinctive brain magnetic resonance imaging. This study suggests that biallelic truncating mutations relate to early-onset disease while non-truncating genotypes contribute to the late-onset manifestation, which was not previously reported in the literature. Interestingly, the newly described case shared characteristics of both phenotypes. In addition, the detailed characterization of this patient's brain MRI abnormalities provides valuable neuroimaging data that have not been previously reported in detail. The findings support a broad disease spectrum and suggest that variant type may influence disease onset and severity. Recognition of characteristic clinical and radiological features may facilitate diagnosis, particularly in patients with suspected prenatal growth retardation and mitochondrial disorders.
- 20 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessClinical spectrum of TOP3A-related disorder: a case report and structured review of reported cases
The enzyme Topoisomerase III alpha (encoded by the gene TOP3A) constitutes an important part of the dissolvasome complex and participates in genomic stability in the nucleus and the mitochondria. Biallelic disease-causing mutations TOP3A are linked to a rare multi-system condition that has some similarities with Bloom syndrome but differentiating characteristics. To further expand the clinical, radiological, and genetic characterization of this condition, we describe a novel patient carrying two previously unreported genetic variants. In addition, a structured review of all previously reported cases in the literature was performed. A total of 27 individuals, among them the newly described patient and patients described in 6 other indexed papers, were included. Two partly overlapping phenotypes were identified: the early-onset type involving prenatal growth retardation, microcephaly, and cardiomyopathy, and the late-onset type involving mitochondrial dysfunction symptoms, such as progressive external ophthalmoplegia, cerebellar ataxia, peripheral neuropathy, as well as distinctive brain magnetic resonance imaging. This study suggests that biallelic truncating mutations relate to early-onset disease while non-truncating genotypes contribute to the late-onset manifestation, which was not previously reported in the literature. Interestingly, the newly described case shared characteristics of both phenotypes. In addition, the detailed characterization of this patient's brain MRI abnormalities provides valuable neuroimaging data that have not been previously reported in detail. The findings support a broad disease spectrum and suggest that variant type may influence disease onset and severity. Recognition of characteristic clinical and radiological features may facilitate diagnosis, particularly in patients with suspected prenatal growth retardation and mitochondrial disorders.
- Open Access
LRP4-Related Congenital Myasthenic Syndrome: Clinical, Pathophysiological, and Therapeutic Aspects
Congenital Myasthenic Syndrome represents a complex and heterogeneous group of inherited neuromuscular disorders, which result from variants in genes involved in different pathophysiological mechanisms related to the neuromuscular junction. LRP4 (Low-density lipoprotein receptor-related protein 4) represents one of the most important proteins involved in this complex signaling pathway, acting in a complex with agrin and Muscle Skeletal Receptor Tyrosine Kinase (MuSK) proteins. LRP4 became known to most neurologists due to the description of anti-LRP4 antibody-related Myasthenia Gravis. There are, however, different neurological and neuromuscular disorders that result from pathogenic variants in LRP4 gene, especially a rare and potentially treatable Congenital Myasthenic Syndrome. The authors performed a detailed narrative review, including descriptions of the main pathophysiological, clinical, and therapeutic aspects of LRP4-related Congenital Myasthenic Syndromes.
Open AccessLRP4-Related Congenital Myasthenic Syndrome: Clinical, Pathophysiological, and Therapeutic Aspects
Congenital Myasthenic Syndrome represents a complex and heterogeneous group of inherited neuromuscular disorders, which result from variants in genes involved in different pathophysiological mechanisms related to the neuromuscular junction. LRP4 (Low-density lipoprotein receptor-related protein 4) represents one of the most important proteins involved in this complex signaling pathway, acting in a complex with agrin and Muscle Skeletal Receptor Tyrosine Kinase (MuSK) proteins. LRP4 became known to most neurologists due to the description of anti-LRP4 antibody-related Myasthenia Gravis. There are, however, different neurological and neuromuscular disorders that result from pathogenic variants in LRP4 gene, especially a rare and potentially treatable Congenital Myasthenic Syndrome. The authors performed a detailed narrative review, including descriptions of the main pathophysiological, clinical, and therapeutic aspects of LRP4-related Congenital Myasthenic Syndromes.
- 6 January 2026
- Published by BMJ in Practical Neurology
- Vol. 26 (5) , 491-494
Arthrogryposis as a neuromuscular phenotype: lessons from PIEZO2 loss-of-function
Arthrogryposis multiplex congenita is a heterogeneous group of disorders characterised by multiple joint contractures resulting from impaired fetal movement. A 43-year-old woman presented with a long-standing congenital clubfoot, progressive scoliosis since childhood and distal joint contractures. She had pure sensory findings, with global areflexia, severe sensory ataxia and a positive Romberg sign, significantly affecting her balance and gait. Genetic analysis identified two likely pathogenic variants in the PIEZO2 gene, consistent with an autosomal recessive inheritance pattern. We discuss the differential diagnosis of arthrogryposis multiplex congenita, emphasising the importance of considering neuromuscular causes. This case highlights the role of comprehensive neurological assessment in patients with distal joint contractures and scoliosis, showing that detailed peripheral neurological findings can guide genetic testing and lead to an accurate diagnosis.
- 6 January 2026
- Published by BMJ in Practical Neurology
- Vol. 26 (5) , 491-494
Arthrogryposis as a neuromuscular phenotype: lessons from PIEZO2 loss-of-function
Arthrogryposis multiplex congenita is a heterogeneous group of disorders characterised by multiple joint contractures resulting from impaired fetal movement. A 43-year-old woman presented with a long-standing congenital clubfoot, progressive scoliosis since childhood and distal joint contractures. She had pure sensory findings, with global areflexia, severe sensory ataxia and a positive Romberg sign, significantly affecting her balance and gait. Genetic analysis identified two likely pathogenic variants in the PIEZO2 gene, consistent with an autosomal recessive inheritance pattern. We discuss the differential diagnosis of arthrogryposis multiplex congenita, emphasising the importance of considering neuromuscular causes. This case highlights the role of comprehensive neurological assessment in patients with distal joint contractures and scoliosis, showing that detailed peripheral neurological findings can guide genetic testing and lead to an accurate diagnosis.
- Open Access
- 5 May 2024
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (5) , 4309-4323
Assessing Chitinases and Neurofilament Light Chain as Biomarkers for Adult-Onset Leukodystrophies
Leukodystrophies represent a large and complex group of inherited disorders affecting the white matter of the central nervous system. Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is a rare leukodystrophy which still needs the proper identification of diagnostic, prognostic, and monitoring biomarkers. The aim of this study was to determine the diagnostic and prognostic value of chitinases and neurofilament light chain as biomarkers for ALSP. A cross-sectional study was performed to analyze cerebrospinal fluid levels of chitinases (chitotriosidase and chitinase 3-like 2) and neurofilament light chain in five different groups: (i) normal health individuals; (ii) patients with definitive diagnosis of ALSP and genetic confirmation; (iii) asymptomatic patients with CSF1R variants; (iv) patients with other adult-onset leukodystrophies; and (v) patients with amyotrophic lateral sclerosis (external control group). Chitinase levels showed a statistical correlation with clinical assessment parameters in ALSP patients. Chitinase levels were also distinct between ALSP and the other leukodystrophies. Significant differences were noted in the levels of chitinases and neurofilament light chain comparing symptomatic (ALSP) and asymptomatic individuals with CSF1R variants. This study is the first to establish chitinases as a potential biomarker for ALSP and confirms neurofilament light chain as a good biomarker for primary microgliopathies.
- 5 May 2024
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (5) , 4309-4323
Open AccessAssessing Chitinases and Neurofilament Light Chain as Biomarkers for Adult-Onset Leukodystrophies
Leukodystrophies represent a large and complex group of inherited disorders affecting the white matter of the central nervous system. Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is a rare leukodystrophy which still needs the proper identification of diagnostic, prognostic, and monitoring biomarkers. The aim of this study was to determine the diagnostic and prognostic value of chitinases and neurofilament light chain as biomarkers for ALSP. A cross-sectional study was performed to analyze cerebrospinal fluid levels of chitinases (chitotriosidase and chitinase 3-like 2) and neurofilament light chain in five different groups: (i) normal health individuals; (ii) patients with definitive diagnosis of ALSP and genetic confirmation; (iii) asymptomatic patients with CSF1R variants; (iv) patients with other adult-onset leukodystrophies; and (v) patients with amyotrophic lateral sclerosis (external control group). Chitinase levels showed a statistical correlation with clinical assessment parameters in ALSP patients. Chitinase levels were also distinct between ALSP and the other leukodystrophies. Significant differences were noted in the levels of chitinases and neurofilament light chain comparing symptomatic (ALSP) and asymptomatic individuals with CSF1R variants. This study is the first to establish chitinases as a potential biomarker for ALSP and confirms neurofilament light chain as a good biomarker for primary microgliopathies.
- 1 July 2018
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 390, 94-98
Leukodystrophy with disorders of sex development due to WT1 mutations
- 1 July 2018
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 390, 94-98
Leukodystrophy with disorders of sex development due to WT1 mutations